viewMotif Bio PLC

Motif Bio says US drugs regulator has encouraged it to carry out further study on antibiotic

The guidance was contained in minutes from a meeting with the Food & Drug Administration in early May

man and woman in lab coats
Motif doesn't know yet what form the new trial will take

Motif Bio PLC (LON:MTFB) (NASDAQ:MTFB) said the US drug regulator has encouraged the company to carry out a further trial on its antibiotic to allay concerns over possible liver toxicity.

At the moment it’s unclear what form the additional assessment will take. The company, in an update, said it had requested a meeting with US Food & Drug Administration to discuss the design of the fresh clinical evaluation, including the appropriate patient population.

Motif is developing iclaprim to treat acute bacterial skin and skin structure infections, and the interaction with the drugs watchdog follows the completion of a phase III trial.

Initial feedback

Initial feedback came in the form of a complete response letter following the trial and then from the minutes of a meeting with the FDA on May 3.

Motif chief executive Graham Lumsden said he thought the drug had a future as he mapped out the next steps, while confirming talks with potential commercial partners were ongoing.

“We intend to meet with the agency to agree on the specific requirements of the trial, which will enable us to estimate its size and scope and, therefore, the costs and funding requirements,” he explained.

Potential alternative indications

As well as a potential new treatment for hospitalised people with acute skin infections, iclaprim could be developed for use in patients with cystic fibrosis or in ophthalmology under what’s called an orphan indication, CEO Lumsden said.

“Completing the steps necessary to provide the additional trial data to respond to the complete response letter is our top priority,” he added.

“We are also continuing our business development activities to position Motif Bio for long-term growth by building a robust development pipeline.

“In parallel with our focus on iclaprim, we continue to pursue a variety of attractive opportunities in the anti-infectives space, as well as in other key therapeutic areas."

In an update on its finances, the company said it had a cash runway “into September”. Unsurprisingly then, it said it is looking to secure additional cash either via an equity raise through other non-dilutive sources.

Quick facts: Motif Bio PLC

Price: 0.5 GBX

Market: AIM
Market Cap: £3.27 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


GinsGlobal Managing Director sees Healthcare and Healthcare innovation as...

HANetf and GinsGlobal Index Funds' Managing Director Anthony Ginsberg joined Steve Darling from Proactive to share details about the success of their Healthcare Innovations ETF. Ginsberg discusses how COVID-19 had made a direct impact on that fund, especially in the telemedicine...

1 day, 1 hour ago

2 min read